Neurogene said it would conduct daily monitoring for the ‘three Fs’ in the week after dosing with the gene therapy.

IQVIA has partnered with SCRI Development Innovations, the contract research organisation side of the Sarah Cannon Research ...

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...

East Coast conference is set to take place on May 20–21, 2025, at the Valley Forge Casino Resort in King of Prussia, ...

AviadoBio has opened the multi-centre Phase I/II ASPIRE-FTD trial in the UK, aimed at assessing the gene therapy candidate ...

Sellas Life Sciences has dosed the first paediatric subject with AML in its Phase II trial of SLS009 (tambiciclib).

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

According to the British Academy of Audiology, hearing loss (HL) is the second most common disability in the UK, affecting ...

Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

Nuance Pharma’s Ohtuvayre has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...